The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making
This revised statement is based on expert opinion and should be interpreted in the context of local policies and emerging
PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data
The COVID-19 pandemic has been a significant concern, and vaccination has been crucial worldwide in its combat.
A research group led by Catherine Smith from St John’s Institute of Dermatology described humoral and cellular immunity.
It is not fully understood the impact that COVID-19 has on psoriasis patients.
The safety of treatment for immune-mediated diseases like psoriasis during the COVID-19 pandemic is a matter of concern. In an
In the April 2021 issue of the Lancet, four of our esteemed colleagues in the IPC published an updated and
Because of the growing body of evidence indicating sex differences in the clinical outcomes of coronavirus disease 2019 (COVID-19) infection,
An article recently published in the Journal of Allergy and Clinical Immunology suggests that diseases such as psoriasis and atopic
